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Abstract 
A coordinated network of molecular circadian clocks in individual cells generates 24-hour 
rhythms in liver metabolism and proliferation. Circadian disruption through chronic jet lag or 
Per2 clock gene mutation was shown to accelerate hepatocarcinoma development in mice. 
Since divergent effects were reported for clock genes Per and Cry regarding xenobiotic 
toxicity, we questioned the role of Cry1 and Cry2 in liver carcinogenesis. 
Male WT and Cry1-/-Cry2-/- mice (C57Bl/6 background) were chronically exposed to 
diethylnitrosamine (DEN) at ZT11. Rest-activity and body temperature rhythms were 
monitored using an implanted radiotransmitter. Serum aspartate and alanine 
aminotransferases (AST, ALT) were determined on four occasions during the progression 
stage. After 7 months, serum alkaline phosphatases (ALP) were determined, and livers were 
sampled for microscopic tumor nodule counting and histopathology.  
Five months after initiation of DEN treatment, we found that Cry1-/-Cry2-/- mice developed 
severe liver dysplasia, as evident from the increased AST, ALT and ALP levels, as compared 
to WT mice. DEN exposure induced primary liver cancers in nearly fivefold as many Cry1-/-
Cry2-/- mice as compared to WT mice (p= 0.01). Microscopic study revealed no difference in 
the average number of hepatocarcinomas and a nearly 8-fold increase in the average number 
of cholangiocarcinomas in Cry1-/-Cry2-/- mice, as compared to WT mice.  
The study validated the hypothesis that molecular circadian clock disruption dramatically 
increased chemically-induced liver carcinogenesis. In addition, the pronounced shift towards 
cholangiocarcinoma in DEN exposed Cry1-/-Cry2-/- mice revealed a critical role of the Cry 
clock genes in bile duct carcinogenesis.  
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Introduction 
Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) constitute the vast majority 
of primary liver cancers, the third cause of cancer-related mortality worldwide. These liver 
cancers are derived from the respective malignant transformation of hepatocytes and bile duct 
epithelial cells 1, 2. Diethylnitrosamine (DEN) is a hepatic carcinogen that usually induces 
HCC in rodents, which have been considered as a good reflection of poor prognosis human 
HCC 3. DEN also induces CCA in mice with bile duct ligation 4, 5. In this study, we used DEN 
as a liver cancer initiator and promoter to investigate the role of circadian genes Cry1 and 
Cry2 for liver carcinogenesis in mice. 
The mammalian Circadian Timing System (CTS) regulates behavioral and physiological 
processes over the 24 hours. Endogenous circadian rhythms are mainly synchronized to the 
regular day-night cycle by light. The liver is one of the most rhythmic organs in the body. 
Prior studies show that approximately 15% of liver transcriptome and proteome display 
circadian variations 6, 7. In addition, a wide range of critical liver metabolic pathways is 
controlled by the circadian clock, involving amino acid, carbohydrate, lipid, nucleotide, and 
xenobiotic metabolism 8, 9. The CTS is coordinated by the suprachiasmatic nucleus (SCN) in 
the hypothalamus, which acts as a central pacemaker. The SCN generates rhythmic 
physiology and coordinates molecular circadian clocks in peripheral organs, including the 
liver 10, 11. The molecular clock, which resides within almost all cells, consists of at least three 
interconnected transcription–translation feedback loops (TTFL) that control rhythmic gene 
expression patterns with a near 24 h period 12. The core TTFL is driven by activator proteins 
BMAL1 and CLOCK or NPAS2, which activate the transcription of target genes containing 
E-box cis-regulatory enhancer sequences, including Period (Per) 1, 2, and 3 genes and 
Cryptochrome (Cry) 1 and 2 genes. In turn, PER::CRY protein heterodimers accumulate in 
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the nucleus and suppress transcription of their own genes by acting on the CLOCK::BMAL1 
protein complex, and as such form the main inhibitory loop of the TTFL 11. 
Several epidemiologic studies, as well as an international expertise by the World Health 
Organisation have concluded that “shift-work that involves circadian disruption is probably 
carcinogenic to humans” 13, 14. Indeed, circadian disruption promotes tumor initiation and 
accelerates experimental cancer progression in mice with SCN ablation, experiencing chronic 
jet lag, or circadian gene mutations, while oppositely CTS reinforcement with meal timing 
inhibits cancer growth 15-20. Host circadian disruption was further associated with fast tumor 
progression and poor survival in cancer patients 21, 22.  
Circadian disruption induced by Per2 mutation, constant light or chronic jet lag exposure has 
been shown to promote DEN-induced liver carcinogenesis, resulting in increased formation of 
a majority of HCC and few CCA in rats and mice 23-25. DEN is usually used for liver cancer 
initiation (2-4 weeks of DEN exposure) and induces the formation of dysplastic foci with 
altered hepatocytes. Prolonged DEN administration is used to act as a cancer promoter (week 
4-10), and induces irreversible hepatocellular nodules 26, 27. Recently, it has been shown that 
Per2 clock gene acts as a tumor suppressor in the liver of mice exposed during 7 weeks to 
DEN. Per2 mutation accelerates hepatocarcinogenesis through uncontrolled proliferation, 
genomic instability, and tumor promoting inflammation. This mutation increases HCC several 
fold without any significant effect on CCA development 25. 
Cry1 and Cry2 are involved in the negative loop of the circadian molecular clock. They are 
robustly expressed and rhythmic in the mouse liver 16, 25. Thus the combined inactivation of 
Cry1 and Cry2 in mice suppressed rest-activity, core body temperature and corticosterone 
secretion following constant darkness exposure 28, 29. The lack of CRY proteins, as in 
Cry1/Cry2 double deficient mice, suppressed the rhythmic expressions of Per1 and Per2 30 
and other E-Box clock or clock-controlled genes 6, 31. In addition, Cry1 and Cry2 genes 
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displayed lower RNA messenger expression, phase shift and dampened amplitude during the 
initiation stage in the liver of WT and Per2 mutant mice exposed to DEN 25. 
 
In order to further test the clock disruption hypothesis as a liver co-carcinogen, we 
hypothesized that chronic exposure to DEN would enhance the rate of liver cancers in mice 
with Cry1/Cry2 double deficiency as compared to WT mice exposed to the same dose of 
DEN. We show that Cry1/Cry2 deficiency increased liver carcinogenesis nearly 5-fold and 
caused a very pronounced shift in tumor spectrum from HCC to CCA. 
 
Materials and Methods  
 
Mice and Study design 
This study was conducted in accordance with the guidelines approved for animal 
experimental procedures by the French Ethical Committee (decree 87-848). 
The effect of Cry1/Cry2 deficiency for DEN-induced liver cancer was investigated in male 
C57Bl/6 mice. Eighteen Wild-Type (WT) and 17 Cry1-/-Cry2-/- mice (obtained from Cry1-/-
Cry2+/- x Cry1+/-Cry2-/- intercrosses) aged 8 to 16 weeks were used. Mice were kept under a 
regular 12 hr light/12 hr dark schedule (LD12:12) at ambient temperature (21°C-23°C) for at 
least 3 weeks before starting DEN administration and throughout experiment, with food and 
water ad libitum. Light intensity at cage level ranged from 240 to 580 lux according to cage 
location. The lights were on from 4:00 (Zeitgeber time, ZT0) to 16:00 (ZT12).  
Sixteen WT and 15 Cry1-/-Cry2-/- mice received a cumulative dose of 406 mg/kg of DEN 
(Sigma-Aldrich, Saint Quentin Fallavier, France), using a 5-days on and 2-days off schedule 
over an overall exposure duration of 68 days. Two control mice per genotype received NaCl 
0.9%. DEN was administered intraperitoneally (i.p.) at ZT11 (1h before darkness onset). 
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Treated mice received daily DEN doses of 12 mg/kg from day 1 to 17, i.e. during the 
carcinogenesis initiation stage. Mice were left DEN-free from day 18 to 28. During the 
subsequent promotion stage, DEN-treated mice received a dose of 10 mg/kg from day 29 to 
33, followed with a 9-days interruption, then re-exposure to 10 mg/kg daily from day 43 to 
68. Body weight was recorded daily before each DEN injection and three times a week 
thereafter. Mortality was checked daily throughout the experiment. Blood was sampled from 
the retro-orbital sinus on days 142, 164, 186, and 211, i.e. during the progression stage. 
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) activities were 
determined four times during the progression stage in the sera using a Synchron LX20 
Clinical System (Beckman Coulter, Villepinte, France). Alkaline phosphatases (ALP) serum 
levels were measured at the last sampling time point. We considered that day 1 to day 21 
corresponded to the initiation stage, day 22 to day 68 to the promotion stage, and day 69 and 
thereafter to the progression stage. All the mice were euthanized 211 days after DEN 
exposure onset. Livers, kidneys, and lungs were removed for pathology and histological 
studies. 
 
Circadian biomarkers 
Prior to DEN-treatment, a Physio Tel TA 10 TA-F20 radiotransmitter (Data Sciences, St. 
Paul, Minnesota) was implanted into the peritoneal cavity under isoflurane anaesthesia in 28 
mice, i.e. 14 Cry1-/-Cry2-/- and 14 WT. These telemetric sensors recorded the rest-activity and 
body temperature rhythms every 10 minutes for 5 days before DEN exposure and for 150 
days thereafter. 
Histological studies 
 
Immediately after sacrifice, mice were autopsied and macroscopic tumor nodules were 
counted. Liver, lungs, and kidneys were collected from each mouse for serial histological 
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slides. All tissues were fixed with 4% formaldehyde for 24 hours, dehydrated, and embedded 
in paraffin. Then, three 4 µm-thick sections were obtained 1 mm apart in each liver and 
stained with hematoxylin-eosin-saffron. Slides were examined blindly for the presence and 
the type of microscopic tumor nodules by a senior pathologist (C.G).  
 
 
Data analyses 
 
Quantitative data were expressed as mean ± standard error of the mean (SEM). Intergroup 
differences were compared using multiple-way analyses of variance (ANOVA), Chi-square, 
T-student and log-rank tests, according to data characteristics. Body temperature and activity 
data were obtained using Dataquest software. The statistical significance of sinusoidal 
rhythmicity was documented by cosinor analysis. This method estimates the rhythm 
characteristics: mesor (24-h mean), amplitude (half of the difference between maximum and 
minimum value of fitted cosine function) and acrophase (time of maximum in fitted cosine 
function, with light onset as phase reference). A rhythm period τ = 24 hours was considered a 
priori. A P-value < 0.05 was considered statistically significant. All statistical analyses were 
performed using SPSS statistical analysis software version 18 (Statistical Package for Social 
Sciences, Chicago, IL). 
 
Results 
 
Systemic toxicity of DEN in WT and Cry1-/-Cry2-/- mice 
 
Mean body weight of both control WT and Cry1-/-Cry2-/- increased slowly over the initial 60 
study days, corresponding to the administration of control solution (by 1.2 and 6.5%, 
respectively). Mean body weight subsequently increased by 9% in WT and 23% in Cry1-/-
Cry2-/- mice on day 180, as compared to day 1. 
After the start of DEN treatment, a marked body weight loss was observed both in WT and in 
Cry1-/-Cry2-/- mice, during the carcinogenesis initiation stage. This led us to reduce the daily 
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DEN dose from 12 to 10 mg/kg. Overall, body weight loss was largest in WT mice as 
compared to Cry1-/-Cry2-/- mice (ANOVA, p< 0.001). Maximum mean body weight loss was 
13.9 ± 1.8 % in WT mice, while it was 7.6 ± 1.5 % in Cry1-/-Cry2-/- mice (Figure 1A). 
Complete body weight recovery was nearly twice as fast in Cry1-/-Cry2-/- as compared to WT 
mice (42 vs 92 days).  
No control mouse died. A single mouse in each genotype group receiving DEN died from 
acute toxicity over the initial two-months’ span. DEN-induced mortality was encountered in 
2/16 WT mice (13%) as compared to 6/15 Cry1-/-Cry2-/- (40%) over the 7-months following 
DEN exposure onset (Log-rank test, p= 0.1) (Figure 1B). Both of the dead WT mice displayed 
histological evidence of liver inflammation and dysplasia, in association with severe body 
weight loss on days 41 (-40%) and 161 (-15%) respectively.  In contrast, Cry1-/-Cry2-/- mice 
displayed (a) severe liver inflammation and dysplasia including apoptotic and necrotic 
hepatocytes, in association with body weight loss (two mice dead on days 33 and 131), (b) 
precancerous liver dysplasia (two mice dead on days 189 and 194), and (c) liver tumor 
nodules (two mice dead on days 204 and 205). Therefore, one death was observed in each 
group during the promotion stage (day 41 for a WT mouse and day 33 for a Cry1-/-Cry2-/- 
mouse), while one WT mice and five Cry1-/-Cry2-/- mice died during the progression stage. 
The tumor nodule counts for these latter two Cry1-/-Cry2-/- mice dead on days 204 and 205 
were combined with those found in the animals euthanized on day 211. 
Serum ALT, AST, and ALP levels were only measured during the progression stage. Serum 
ALT activity was significantly increased in mice of both genotypes on days 186 and 211 only, 
with levels that were nearly doubled in Cry1-/-Cry2-/- mice as compared to WT animals (p< 
0.05) (Figure 1C). From days 142 to 211, AST serum activity was increased in DEN-treated 
WT and Cry1-/-Cry2-/- mice, as compared to untreated control animals. AST activity was ~1.6-
fold as high on days 142 and 164, and twice as high on days 186 and 211 for Cry1-/-Cry2-/- 
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treated mice as compared to treated-WT (p< 0.01 to p< 0.05) (Figure 1D). ALP levels 
remained unaltered in DEN treated WT mice, while they were doubled in Cry1-/-Cry2-/- mice 
as compared to untreated control animals. Indeed, on DEN exposure, serum ALP 
concentration increased three-fold in Cry1-/-Cry2-/- mice as compared to WT mice on day 211 
(p< 0.01) (Figure 1E). 
 
Baseline rest-activity and body temperature patterns in WT and Cry1-/-Cry2-/- mice 
before DEN exposure and throughout the liver carcinogenesis process 
Rest-activity and body temperature circadian biomarkers were recorded by telemetry, starting 
5 days before DEN exposure onset and continuing until 150 days after it. Prior to carcinogen 
administration, regular 24-h changes were found for rest-activity and body temperature in WT 
mice. The 24-h patterns in both variables were severely altered in Cry1-/-Cry2-/- mice (Figure 
2A). As a result, cosinor analysis validated statistically significant rhythms, with different 
characteristics according to genotype. Thus, a phase advance was found in Cry1-/-Cry2-/- mice 
by 3 h and 10 min for rest-activity (ZT15:40 vs ZT18:50; p<0.001) and by 1 h and 50 min for 
body temperature (ZT16:20 vs ZT18:10; p= 0.025) as compared to WT (Figure 2B). The 
circadian amplitude was nearly reduced by half for both rest-activity (Hoteling t-test for 
amplitude comparisons, 1.05 ± 0.27 vs 2.09 ±0.22 arb. units, p< 0.001), and body temperature 
(0.53 ± 0.07 vs 0.96 ± 0.02°C, p< 0.001) in Cry1-/-Cry2-/- animals as compared to WT mice 
(Figure 2C). 
In Cry1-/-Cry2-/- mice, DEN administration supressed the circadian rhythm in rest-activity for 
6/14 mice (40%) and that in body temperature for 4/14 animals (28%) during the initiation 
and/or promotion and progression stages. In contrast, no circadian rhythm loss was observed 
for both variables in WT mice. Interestingly, the rest-activity and/or temperature circadian 
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rhythms were completely suppressed during the initiation/promotion stages for four of the six 
Cry1-/- Cry2-/- mice, which subsequently died before study completion.  
During the initiation stage, DEN exposure further advanced the rest-activity circadian phase 
by 2 hours in WT (p< 0.001), without any significant alteration in Cry1-/-Cry2-/- mice as 
compared to baseline values before DEN exposure. In contrast, the temperature circadian 
phase was advanced by ~1 h in WT and ~1 h and 30 min in Cry1-/-Cry2-/- mice (paired T-test, 
p< 0.001) (Figure 2B). In WT animals, DEN halved the circadian amplitude for rest-activity 
and damped it by 20% for body temperature as compared to their respective baseline values 
(Hoteling t-test for amplitude comparisons, p< 0.001 and p= 0.03 respectively). The circadian 
amplitude for rest-activity rhythm was halved in DEN treated Cry1-/-Cry2-/- mice (p= 0.003) 
while it was 1.6-fold lower for body temperature rhythm as compared to baseline values 
(Figure 2C). 
A nearly 1-h phase advance was statistically confirmed during the promotion stage for both 
rest-activity and body temperature rhythms in WT mice (p= 0.09 and p< 0.001 respectively) 
as compared to their baseline values before DEN exposure. Cry1-/-Cry2-/- mice did not display 
any significant change for rest-activity phase, while cosinor analysis validated a 2-h phase 
advance for body temperature (ZT16:20 vs ZT14:30, p= 0.03) (Figure 2B). During this 
carcinogenesis stage, DEN dampened the circadian amplitude by 37% and 15% for both rest-
activity and body temperature rhythms respectively in WT mice (p< 0.001). Moreover, this 
effect was more pronounced in Cry1-/-Cry2-/- mice, and the circadian amplitude was nearly 
halved for both rhythms (p=0.01 for rest-activity, and p=0.03 for body temperature) (Figure 
2C). After DEN exposure, the circadian acrophases and amplitudes of both rhythms recovered 
back to baseline values in the mice from both genotypes. Double-plot representations of both 
body temperature and rest-activity rhythms in individual mice over 130 days showed stable 
rhythms in WT controls mice and markedly damped, yet persistent rhythms in control Cry1-/-
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Cry2-/- animals (Figure 3). Indeed, the daily intraperitoneal injections of the control solution 
induced minimal if any alteration in the rest-activity and intraperitoneal temperature patterns 
in both control WT and both control Cry1-/-Cry2-/- mice, which matched the corresponding 
DEN-treated groups (Figure 3, Suppl Tables 1 and 2). DEN exposure transiently disrupted 
both circadian rhythms during the initiation and the promotion stages in WT mice. Both 
rhythms subsequently recovered during the progression stage. In contrast, the disruption of 
both rhythms was complete and sustained until the end of the recording in Cry1-/-Cry2-/- mice 
exposed to the same DEN cumulative dose (Figures 3A and B). 
 
DEN induced liver carcinogenesis in WT and Cry1-/-Cry2-/- mice 
 
Macroscopic nodules, together with small and large liver cell dysplasia, inflammatory 
infiltration and apoptotic hepatocytes, were observed in 17 of 25 remaining mice at 7 months 
(Figure 4 A and B). Control mice with either genotype exhibited normal liver histology 
(Figure 4 C and D). However, DEN exposure resulted in many more primary biliary lesions in 
Cry1-/-Cry2-/- as compared to WT mice (Figure 4 E and F). Both CCA’s and HCC’s could be 
found in animals from both genotypes (Figure 4 G and H). DEN also induced lung 
tubulopapillary tumors in 5 WT and 3 Cry1-/-Cry2-/- mice. A single primary tumor was found 
in the kidney of one Cry1-/-Cry2-/- mouse. 
Liver tumors were found in 43 % of WT and in all Cry1-/-Cry2-/- mice (p< 0.001). The average 
number of tumors per animal including CCA and HCC was nearly five-fold higher in Cry1-/-
Cry2-/- mice as compared to WT animals (Kruskal-Wallis, p= 0.01) (Figure 5A). The number 
of tumor nodules per liver ranged from 0 to 7 in WT and from 1 to 25 in Cry1-/-Cry2-/- mice 
(Fisher‘s exact test, p= 0.003). In addition, the proportion of mice with more than 2 tumors 
was ~six-fold higher in Cry1-/-Cry2-/- mice as compared to WT animals (80% vs 14%, Fisher‘s 
exact test, p= 0.01). 
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In Cry1-/-Cry2-/- mice, histopathological analysis revealed ~24 times as many CCA as 
compared to HCC (73 vs 3; p< 0.001). However, WT mice did not display any significant 
difference for liver cancer types (Figure 5B). The average number of CCA per mouse was 7.8 
fold as high in Cry1-/-Cry2-/- mice as compared to WT mice (p< 0.01), while no validated 
difference was detected for HCC (Figure 5B). 
 
Discussion 
Here we validated the hypothesis that chronic exposure to DEN enhanced several-fold the rate 
of liver cancers in mice with a Cry1/Cry2 double deficiency as compared to WT mice 
exposed to the same dose of DEN.  This was consistent with the findings we earlier reported 
in Per2m/m mice, which harboured another clock gene deficiency 25. However 
histopathological examination by a senior liver cancer pathologist revealed that the vast 
majority of liver cancers were cholangio- rather than hepato-carcinomas in the Cry1/Cry2 
double deficient mice. To our knowledge, this is the first study that reveals a direct role of 
Cry1 and Cry2 genes in CCA. Notably, the deficiency of Cry1 and Cry2 caused a nearly 8-
fold increase in the average number of CCA induced by the hepatic carcinogen DEN in mice.  
 
Cry1-/-Cry2-/- mice displayed genetic circadian disruption, as indicated by arrhythmic body 
temperature, rest-activity, and corticosterone secretion while in constant darkness 28, 29. 
However, a 24-h rhythm in rest-activity and body temperature was found here in Cry1-/-Cry2-/- 
mice exposed to LD12:12, yet with 2 to 3-h phase advance and halved amplitude. These 
apparent rhythms in clock-deficient Cry1-/-Cry2-/- mice likely originated from direct responses 
to light, so called masking effect 28. 
Cry1/Cry2 double deficient mice were also shown to display enhanced susceptibility to 
develop spontaneous or gamma radiation-induced HCC as compared to WT animals, without 
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any reported evidence of CCA formation in their livers 19, 32. In contrast, we did find both 
HCC’s and CCA’s in WT B6D2F1 mice kept in LD12:12 or chronically exposed to jet lag 
and receiving DEN 24, as well as both in WT and in Per2m/m mice on chronic DEN 25. The 
current study revealed a low incidence of DEN-induced HCC both in WT and in Cry1/Cry2 
double deficient mice on C57Bl/6 background. Yet the large and highly statistically 
significant difference in CCA formation most likely resulted from altered DEN metabolism 
and toxicodynamics in the Cry1/Cry2 double deficient mice. The differences in DEN 
metabolism and toxicodynamics between Cry1/Cry2 double deficient and Per2m/m mice thus 
appeared to be crucial for the cancer type outcomes. 
 
The role of Cry1/Cry2 double deficiency for liver carcinogenesis was here investigated in 
mice on a C57Bl/6 background, with altered melatonin secretion. Gas chromatography (GC)-
mass spectrometry (MS) studies have demonstrated melatonin in the pineal gland and in 
peripheral blood of C57BL/6, BALB/c and C57BL/6 x DBA2 (B6D2F1) mice, which were 
previously deemed to lack any melatonin secretion 33, 34. However, melatonin secretion was 
weak, and its circadian pattern was shifted or bimodal, as compared to the prominent 
melatonin secretory patterns in C3H and CBA mice 33, 34. Hence, our study could not robustly 
assess any effect of endogenous melatonin secretion on DEN carcinogenesis, or its 
impairment in clock-mutant mice. Nonetheless, the anticarcinogenic effects of melatonin 
against liver carcinogenesis remain an important issue. In rats, melatonin prevented 
chemically-induced hepatocarcinogenesis by reversing the oxidant-antioxidant imbalance 
during DEN exposure 35, 36, while in vitro exogenous melatonin induced apoptosis in 
cholangiocarcinoma cell lines 37. Interestingly, a Cry1/Cry2 double deficiency has been 
shown to both decrease mean level and suppress the circadian melatonin secretory pattern in 
C3H mice 38. Accordingly, we would expect DEN-induced liver carcinogenesis to be reduced 
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in melatonin-proficient C3H mice, while being doubly enhanced both by circadian clock 
disruption and melatonin suppression in cryptochromes deficient C3H mice. 
 
Decreased mRNA or protein expressions of Cry1 and/or Cry2, were reported for human HCC, 
as well as for human cancers of the breast, endometrium, ovary, prostate, colon, pancreas, 
head-and-neck, brain, skin and blood cells 39-42. Yet, the relevance of Cry1/Cry2 deficiency 
for carcinogenesis was debated. A prior report showed that Cry1/Cry2 deficiency promoted γ-
radiation-induced lymphomas in mice 19. This could result from increased cell cycling, since 
Cry1-/-Cry2-/- fibroblasts were shown to proliferate faster than WT fibroblasts 43. However, 
both of these latter findings 19, 43 contrasted with another report where Cry1/Cry2 deficiency 
had no effect on γ-radiation-induced carcinogenesis and mortality in mice 44. This latter 
finding was also in line with the lack of any up-regulation of the proto-oncogene c-Myc in 
Cry1-/- Cry2-/- mouse liver and fibroblasts following radiation exposure, as well as the lack of 
modifications of cell cycle checkpoints, DNA repair, or apoptosis in Cry deficient fibroblasts 
44. Moreover, the combination of Cry1/Cry2 deficiency with p53 deletion protected mice from 
the early onset of γ-radiation-induced cancers and increased their median lifespan 45, 46. 
However, our study unambiguously demonstrated a dramatic and unexpected CCA effect of 
DEN in mice with a Cry1/Cry2 double deficiency. The magnitude of such effect was 
apparently unrelated to that of DEN toxicity. Thus, body weight loss, a marker of systemic 
toxicity, was least in Cry1-/-Cry2-/- mice, a finding consistent with increased tolerability of 
Cry1-/-Cry2-/- mice to the alkylating drug cyclophosphamide 47. In contrast, Per2 mutant mice 
exposed to DEN displayed larger body weight loss as compared to their control 25. Taken 
together, the results support CYP-mediated bioactivation of both DEN and cyclophosphamide 
was decreased in Cry1-/-Cry2-/- and enhanced in Per2m/m mice. Thus, Cry1 and Cry2 genes 
would be primarily involved in the promotion and progression stages, while having reduced 
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impact on initiation stage. This conclusion is also supported by the fact that Cry1/Cry2 
deficient mice displayed lower liver regeneration 72 hours after partial hepatectomy, 
associated with a high level of WEE1, which blocks G2-M transition 48. 
DEN-induced liver carcinogenesis involves initial triggering of chronic inflammation 49, 50. 
More specifically, CCA risk factors involve chronic biliary inflammation. According to 
several reports, pro-inflammatory cytokine IL-6 was up-regulated in cultured CCA cells, 
resulting in the activation of the JAK-STAT and NF-kB signalling pathways 51, 52. IL-6 further 
increased Mcl-1 through STAT-3 activation, and prevented apoptosis in CCA cells 51, 52. In 
addition, IL-6 upregulation in CCA dysregulated the cell division cycle through the activation 
of P38 MAPK 53. Indeed, several studies showed an important role of NF-kB activation in 
cholangiocarcinogenesis 54, 55. The silencing of Cry1 and Cry2 enhanced lipopolysaccharide-
induced inflammatory response through increased NF-κB and IL-6 activation in mouse 
hypothalamus, bone marrow macrophages, and fibroblasts 29, 56. It has been shown that CRY1 
protein bind to adenylyl cyclase and induces cAMP downregulation. In Cry1-/-Cry2-/- cells, the 
inhibition of adenylyl-cyclase, leads to cAMP upregulation, PKA activation, P65 (a subunit of 
NF-kB complex) phosphorylation, and activation of NF-kB target genes such as IL-6 56. Thus, 
the increased biliary carcinogenesis found in Cry1-/-Cry2-/- mice exposed could result from an 
enhanced susceptibility to pre-existing and/or DEN-induced chronic biliary inflammation.  
 
In contrast to the finding showing that Per2 mutant mice are more susceptible to develop 
HCC 25, Cry1-/-Cry2-/- deficient mice were more sensitive to DEN-induced CCA. WT mice 
subjected to left median bile duct ligation after 2 weeks of DEN exposure, then exposed to 
DEN, showed an increased susceptibility to develop CCA 4. We suggest that the Cry1/Cry2 
double deficiency acts, like bile duct ligation, through accumulation of toxic bile acids in the 
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liver during the promotion stage, and thus would shift the cancer susceptibility of mice from 
HCC to CCA. 
Although toxic bile acid accumulation increased liver susceptibility to develop HCC in 
animals, bile duct ligation-mediated toxic bile acid accumulation has also been shown to 
enhance CCA development 57, 58. Bile acid accumulation locally altered proliferation and 
apoptosis (and even more so during cholestasis), which further predisposed to 
cholangiocarcinogenesis 59, 60. Indeed, mice with bile duct ligation exposed to DEN displayed 
clearly accelerated CCA rather than HCC development 4. Thus CCA occurred in 2.5 times as 
many mice with bile duct ligation as compared to those without such procedure (50% vs 
20%), while the rate of HCC remained similar (20 %) in both groups 4. Importantly, the CCA 
to HCC ratio was also largely positive and even greater in Cry1-/-Cry2-/- vs WT mice in our 
study, suggesting additional metabolic effects of the cryptochromes double deficiency. 
Interestingly the Per1-/-Per2-/- mice, whose circadian phenotype closely resembles that of 
Cry1-/-Cry2-/- animals, displayed elevated serum bile acid levels, while the circadian 
expression of key bile acid synthesis and transport genes (including Cyp7A1 and NTCP) was 
lost 61. In aggregate, these reports, and our findings jointly support cholestasis and toxic bile 
acid accumulation to result from Cry1/Cry2 double deficiency, and to shift DEN liver 
carcinogenesis from HCC toward CCA formation. 
 
The current study has unambiguously validated that circadian clock disruption through 
Cry1/Cry2 double deficiency more than doubled the incidence of diethylnitrosamine-induced 
liver cancers, with adequate statistical power. Eight times more cholangiocarcinomas were 
found in Cry1-/-Cry2-/- as compared to WT mice, while nearly 10% HCC occurred in both 
genotypes. We inferred that such major shift from HCC to CCA in the DEN liver 
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carcinogenesis model resulted from accumulated bile acids and cholestasis in the Cry double 
deficient mice. 
 
References 
Uncategorized References 
 1. Mancuso A. Management of hepatocellular carcinoma: Enlightening the gray zones. 
World J Hepatol 2013;5: 302-10. 
 2. Zabron A, Edwards RJ, Khan SA. The challenge of cholangiocarcinoma: dissecting 
the molecular mechanisms of an insidious cancer. Dis Mod Mech 2013;6: 281-92. 
 3. Lee JS, Grisham JW, Thorgeirsson SS. Comparative functional genomics for 
identifying models of human cancer. Carcinogenesis 2005;26: 1013-20. 
 4. Yang H, Li TW, Peng J, Tang X, Ko KS, Xia M, Aller MA. A mouse model of 
cholestasis-associated cholangiocarcinoma and transcription factors involved in progression. 
Gastroenterology 2011;141: 378-88, 88 e1-4. 
 5. De Minicis S, Kisseleva T, Francis H, Baroni GS, Benedetti A, Brenner D, Alvaro 
D, Alpini G, Marzioni M. Liver carcinogenesis: rodent models of hepatocarcinoma and 
cholangiocarcinoma. Dig Dis Liver 2013;45: 450-9. 
 6. Vollmers C, Gill S, DiTacchio L, Pulivarthy SR, Le HD, Panda S. Time of feeding 
and the intrinsic circadian clock drive rhythms in hepatic gene expression. Proc Natl Acad Sci 
U S A 2009;106: 21453-8. 
 7. Schmutz I, Albrecht U, Ripperger JA. The role of clock genes and rhythmicity in 
the liver. Mol Cell Endocrinol 2012;349: 38-44. 
 8. Eckel-Mahan KL, Patel VR, Mohney RP, Vignola KS, Baldi P, Sassone-Corsi P. 
Coordination of the transcriptome and metabolome by the circadian clock. Proc Natl Acad Sci 
U S A 2012;109: 5541-6. 
 9. Fustin JM, Doi M, Yamada H, Komatsu R, Shimba S, Okamura H. Rhythmic 
nucleotide synthesis in the liver: temporal segregation of metabolites. Cell Rep 2012;1: 341-9. 
 10. Kornmann B, Schaad O, Reinke H, Saini C, Schibler U. Regulation of circadian 
gene expression in liver by systemic signals and hepatocyte oscillators. Cold Spring Harb 
Symp Quant Biol 2007;72: 319-30. 
 11. Mohawk JA, Green CB, Takahashi JS. Central and peripheral circadian clocks in 
mammals. Annu Rev Neurosci 2012;35: 445-62. 
 12. Partch CL, Green CB, Takahashi JS. Molecular architecture of the mammalian 
circadian clock. Trends Cell Biol 2013. 2014 Feb;24(2):90-9. doi: 10.1016/j.tcb.2013.07.002 
 13. Straif K, Baan R, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, Altieri A, 
Benbrahim-Tallaa L, Cogliano V. Carcinogenicity of shift-work, painting, and fire-fighting. 
Lancet Oncol 2007;8: 1065-6. 
 14. Wang F, Yeung KL, Chan WC, Kwok CC, Leung SL, Wu C, Chan EY, Yu IT, 
Yang XR, Tse LA. A meta-analysis on dose-response relationship between night shift work 
and the risk of breast cancer. Ann Oncol 2013;24: 2724-32. 
 15. Filipski E, King VM, Li X, Granda TG, Mormont MC, Liu X, Claustrat B, 
Hastings MH, Levi F. Host circadian clock as a control point in tumor progression. J Natl 
Cancer Inst 2002;94: 690-7. 
19 
 
 16. Filipski E, Innominato PF, Wu M, Li XM, Iacobelli S, Xian LJ, Levi F. Effects of 
light and food schedules on liver and tumor molecular clocks in mice. J Natl Cancer Inst 
2005;97: 507-17. 
 17. Li XM, Delaunay F, Dulong S, Claustrat B, Zampera S, Fujii Y, Teboul M, Beau 
J, Levi F. Cancer inhibition through circadian reprogramming of tumor transcriptome with 
meal timing. Cancer Res 2010;70: 3351-60. 
 18. Fu L, Pelicano H, Liu J, Huang P, Lee C. The circadian gene Period2 plays an 
important role in tumor suppression and DNA damage response in vivo. Cell 2002;111: 41-
50. 
 19. Lee S, Donehower LA, Herron AJ, Moore DD, Fu L. Disrupting circadian 
homeostasis of sympathetic signaling promotes tumor development in mice. PLoS One 
2010;5: e10995. 
 20. Van Dycke KC, Rodenburg W, van Oostrom CT, van Kerkhof LW, Pennings JL, 
Roenneberg T, van Steeg H, van der Horst GT. Chronically alternating light cycles increase 
breast cancer risk in mice. Curr Biol 2015;25: 1932-7. 
 21. Innominato PF, Giacchetti S, Bjarnason GA, Focan C, Garufi C, Coudert B, 
Iacobelli S, Tampellini M, Durando X, Mormont MC, Waterhouse J, Levi FA. Prediction of 
overall survival through circadian rest-activity monitoring during chemotherapy for metastatic 
colorectal cancer. Int J Cancer 2012;131: 2684-92. 
 22. Ortiz-Tudela E, Mteyrek A, Ballesta A, Innominato PF, Levi F. Cancer 
chronotherapeutics: experimental, theoretical, and clinical aspects. Handb Exp Pharmacol 
2013: 261-88. 
 23. van den Heiligenberg S, Depres-Brummer P, Barbason H, Claustrat B, Reynes M, 
Levi F. The tumor promoting effect of constant light exposure on diethylnitrosamine-induced 
hepatocarcinogenesis in rats. Life Sci 1999;64: 2523-34. 
 24. Filipski E, Subramanian P, Carriere J, Guettier C, Barbason H, Levi F. Circadian 
disruption accelerates liver carcinogenesis in mice. Mutat Res 2009;680: 95-105. 
 25. Mteyrek A, Filipski E, Guettier C, Okyar A, Levi F. Clock gene Per2 as a 
controller of liver carcinogenesis. Oncotarget 2016;7: 85832-47. 
 26. Williams GM, Iatropoulos MJ, Wang CX, Ali N, Rivenson A, Peterson LA, 
Schulz C, Gebhardt R. Diethylnitrosamine exposure-responses for DNA damage, 
centrilobular cytotoxicity, cell proliferation and carcinogenesis in rat liver exhibit some non-
linearities. Carcinogenesis 1996;17: 2253-8. 
 27. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer 
development and progression. Nat Rev Immunol 2005;5: 749-59. 
 28. van der Horst GT, Muijtjens M, Kobayashi K, Takano R, Kanno S, Takao M, de 
Wit J, Verkerk A, Eker AP, van Leenen D, Buijs R, Bootsma D, et al. Mammalian Cry1 and 
Cry2 are essential for maintenance of circadian rhythms. Nature 1999;398: 627-30. 
 29. Lamia KA, Papp SJ, Yu RT, Barish GD, Uhlenhaut NH, Jonker JW, Downes M, 
Evans RM. Cryptochromes mediate rhythmic repression of the glucocorticoid receptor. 
Nature 2011;480: 552-6. 
 30. Okamura H, Miyake S, Sumi Y, Yamaguchi S, Yasui A, Muijtjens M, 
Hoeijmakers JH, van der Horst GT. Photic induction of mPer1 and mPer2 in cry-deficient 
mice lacking a biological clock. Science 1999;286: 2531-4. 
 31. Oishi K, Miyazaki K, Kadota K, Kikuno R, Nagase T, Atsumi G, Ohkura N, 
Azama T, Mesaki M, Yukimasa S, Kobayashi H, Iitaka C, et al. Genome-wide expression 
analysis of mouse liver reveals CLOCK-regulated circadian output genes. J Biol Chem 
2003;278: 41519-27. 
20 
 
 32. Kettner NM, Voicu H, Finegold MJ, Coarfa C, Sreekumar A, Putluri N, Katchy 
CA, Lee C, Moore DD, Fu L. Circadian homeostasis of liver metabolism suppresses 
hepatocarcinogenesis. Cancer Cell 2016;30: 909-24. 
 33. Vivien-Roels B, Malan A, Rettori MC, Delagrange P, Jeanniot JP, Pevet P. Daily 
variations in pineal melatonin concentrations in inbred and outbred mice. J Biol Rhythms 
1998;13: 403-9. 
 34. Li XM, Liu XH, Filipski E, Metzger G, Delagrange P, Jeanniot JP, Levi F. 
Relationship of atypical melatonin rhythm with two circadian clock outputs in B6D2F(1) 
mice. Am J Physiol Regul Integr Comp Physiol 2000;278: R924-30. 
 35. Dakshayani KB, Subramanian P, Manivasagam T, Essa MM, Manoharan S. 
Melatonin modulates the oxidant-antioxidant imbalance during N-nitrosodiethylamine 
induced hepatocarcinogenesis in rats. J Pharm Pharm Sci 2005;8: 316-21. 
 36. Subramanian P, Mirunalini S, Dakshayani KB, Pandi-Perumal SR, Trakht I, 
Cardinali DP. Prevention by melatonin of hepatocarcinogenesis in rats injected with N-
nitrosodiethylamine. J Pineal Res 2007;43: 305-12. 
 37. Laothong U, Hiraku Y, Oikawa S, Intuyod K, Murata M, Pinlaor S. Melatonin 
induces apoptosis in cholangiocarcinoma cell lines by activating the reactive oxygen species-
mediated mitochondrial pathway. Oncol Rep 2015;33: 1443-9. 
 38. Yamanaka Y, Suzuki Y, Todo T, Honma K, Honma S. Loss of circadian rhythm 
and light-induced suppression of pineal melatonin levels in Cry1 and Cry2 double-deficient 
mice. Genes Cells 2010;15: 1063-71. 
 39. Mazzoccoli G, Piepoli A, Carella M, Panza A, Pazienza V, Benegiamo G, 
Palumbo O, Ranieri E. Altered expression of the clock gene machinery in kidney cancer 
patients. Biomed Pharmacother 2012;66: 175-9. 
 40. Lengyel Z, Lovig C, Kommedal S, Keszthelyi R, Szekeres G, Battyani Z, Csernus 
V, Nagy AD. Altered expression patterns of clock gene mRNAs and clock proteins in human 
skin tumors. Tumour Biol 2013;34: 811-9. 
 41. Mazzoccoli G, Colangelo T, Panza A, Rubino R, De Cata A, Tiberio C, Valvano 
MR, Pazienza V, Merla G, Augello B, Trombetta D, Storlazzi CT, et al. Deregulated 
expression of cryptochrome genes in human colorectal cancer. Mol Cancer 2016;15: 6. 
 42. Fu L, Kettner NM. The circadian clock in cancer development and therapy. Prog 
Mol Biol Transl Sci 2013;119: 221-82. 
 43. Destici E, Oklejewicz M, Saito S, van der Horst GT. Mammalian cryptochromes 
impinge on cell cycle progression in a circadian clock-independent manner. Cell Cycle 
2011;10: 3788-97. 
 44. Gauger MA, Sancar A. Cryptochrome, circadian cycle, cell cycle checkpoints, and 
cancer. Cancer Res 2005;65: 6828-34. 
 45. Ozturk N, Lee JH, Gaddameedhi S, Sancar A. Loss of cryptochrome reduces 
cancer risk in p53 mutant mice. Proc Natl Acad Sci U S A 2009;106: 2841-6. 
 46. Lee JH, Sancar A. Circadian clock disruption improves the efficacy of 
chemotherapy through p73-mediated apoptosis. Proc Natl Acad Sci U S A 2011;108: 10668-
72. 
 47. Gorbacheva VY, Kondratov RV, Zhang R, Cherukuri S, Gudkov AV, Takahashi 
JS, Antoch MP. Circadian sensitivity to the chemotherapeutic agent cyclophosphamide 
depends on the functional status of the CLOCK/BMAL1 transactivation complex. Proc Natl 
Acad Sci U S A 2005;102: 3407-12. 
 48. Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F, Okamura H. Control 
mechanism of the circadian clock for timing of cell division in vivo. Science 2003;302: 255-9. 
21 
 
 49. Maeda S, Kamata H, Luo JL, Leffert H, Karin M. IKKbeta couples hepatocyte 
death to cytokine-driven compensatory proliferation that promotes chemical 
hepatocarcinogenesis. Cell 2005;121: 977-90. 
 50. Sun B, Karin M. Inflammation and liver tumorigenesis. Front Med 2013;7: 242-
54. 
 51. Kobayashi S, Werneburg NW, Bronk SF, Kaufmann SH, Gores GJ. Interleukin-6 
contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in 
cholangiocarcinoma cells. Gastroenterology 2005;128: 2054-65. 
 52. Isomoto H, Mott JL, Kobayashi S, Werneburg NW, Bronk SF, Haan S, Gores GJ. 
Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic 
silencing. Gastroenterology 2007;132: 384-96. 
 53. Tadlock L, Patel T. Involvement of p38 mitogen-activated protein kinase signaling 
in transformed growth of a cholangiocarcinoma cell line. Hepatology 2001;33: 43-51. 
 54. Zhou Q, Gong Y, Huang F, Lin Q, Zeng B, Li Z, Chen R. Expression levels and 
significance of nuclear factor-kappaB and epidermal growth factor receptor in hepatolithiasis 
associated with intrahepatic cholangiocarcinoma. Dig Surg 2013;30: 309-16. 
 55. Dai J, Wang H, Dong Y, Zhang Y, Wang J. Bile acids affect the growth of human 
cholangiocarcinoma via NF-kB pathway. Cancer Invest 2013;31: 111-20. 
 56. Narasimamurthy R, Hatori M, Nayak SK, Liu F, Panda S, Verma IM. Circadian 
clock protein cryptochrome regulates the expression of proinflammatory cytokines. Proc Natl 
Acad Sci U S A 2012;109: 12662-7. 
 57. Zhang Y, Hong JY, Rockwell CE, Copple BL, Jaeschke H, Klaassen CD. Effect of 
bile duct ligation on bile acid composition in mouse serum and liver. Liver Int 2012;32: 58-
69. 
 58. Lozano E, Sanchez-Vicente L, Monte MJ, Herraez E, Briz O, Banales JM, Marin 
JJ, Macias RI. Cocarcinogenic effects of intrahepatic bile acid accumulation in 
cholangiocarcinoma development. Mol Cancer Res 2014;12: 91-100. 
 59. Yoon JH, Higuchi H, Werneburg NW, Kaufmann SH, Gores GJ. Bile acids induce 
cyclooxygenase-2 expression via the epidermal growth factor receptor in a human 
cholangiocarcinoma cell line. Gastroenterology 2002;122: 985-93. 
 60. Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of 
cholangiocarcinoma. Gastroenterology 2013;145: 1215-29. 
 61. Ma K, Xiao R, Tseng HT, Shan L, Fu L, Moore DD. Circadian dysregulation 
disrupts bile acid homeostasis. PLoS One 2009;4: e6843. 
 
Figure legends 
 
Fig. 1. Systemic toxicity of DEN in WT and Cry1-/-Cry2-/- mice during the initiation, 
promotion, and progression carcinogenesis stages. (A) Relative body weight changes 
(mean ± SEM) in WT and Cry1-/-Cry2-/- mice throughout carcinogenesis stages. Weight loss 
was largest in WT mice (dark triangles) as compared to Cry1-/-Cry2-/- animals (open triangles). 
The daily DEN doses (mg/kg) are shown in italics, for corresponding exposure spans. (B) 
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Survival rate in WT (dark triangles) and Cry1-/-Cry2-/- (open triangles) mice exposed to DEN 
at ZT11. (C) Histogram of ALT serum activity (mean ± SEM) after DEN exposure of WT 
(dark box) and Cry1-/-Cry2-/- (open box) mice. (D) Serum level of AST (mean ± SEM) in WT 
(dark box) and Cry1-/-Cry2-/- (open box) mice. (E) Serum concentrations of ALP in WT and 
Cry1-/-Cry2-/- mice on day 211. Mean (± SEM) ALT, AST and ALP serum levels in untreated 
control mice are represented by gray horizontal bars.  * p < 0.05; ** p < 0.01  
 
Fig. 2. Rest-activity and body temperature patterns and circadian parameters in WT 
and Cry1-/-Cry2-/- mice throughout liver carcinogenesis. (A) Examples of rest-activity and 
body temperature patterns in a WT mouse (left) and in a Cry1-/-Cry2-/- mouse (right) before 
DEN exposure. (B) Circadian acrophase changes for rest-activity (left panel) and body 
temperature (right panel) in WT (dark triangles) and Cry1-/-Cry2-/- (open triangles) animals 
before and during initiation (weeks 1-3), promotion (weeks 4-10), and progression (weeks 11-
30) carcinogenesis stages. (C) Corresponding histograms of 24-h mean amplitudes with 95% 
C.L. for rest-activity (left panel) and body temperature (right panel) in WT (dark boxes) and 
Cry1-/-Cry2-/-  (open boxes) mice before and throughout liver carcinogenesis stages. ** p< 
0.01; *** p< 0.001. 
Fig. 3. Examples of circadian activity and temperature rhythms records over 130 days in 
mice according to Cry1/Cry2 double deficiency and DEN exposure. Representative double 
plot of 24-h rhythms in intraperitoneal temperature (A) and rest-activity (B) in WT and Cry1-/-
Cry2-/- mice. The vertical black lines indicate exposure to DEN or vehicle (for 68 days). 
Fig. 4. Representative histological slides of DEN-induced liver alterations in WT and 
Cry1/ Cry2 double knock-out mice on the completing of the study (Day 211). 
Typical macroscopic view of a deeply reorganized liver with macroscopic nodules (circled in 
white) arising in a WT mouse (A) and a Cry1-/-Cry2-/- animal (B). Microscopic view (x10) of 
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untreated WT (C) or Cry1-/-Cry2-/- control mice (D). Microscopic view (x10) of primary 
lesions (arrows) in WT (E) or Cry1-/-Cry2-/- mice (F). Detailed microscopic view (x20) of 
cholangiocarcinoma (G) and hepatocarcinoma (H). 
 
Fig. 5. DEN-induced liver cancer according to Cry1/Cry2 double deficiency. (A) Number 
of tumor nodules per mouse liver in WT (black box) and in Cry1-/-Cry2-/- mice (open box). 
(B) Average number of hepatocarcinomas (open box) and cholangiocarcinomas (grey box) in 
WT and Cry1-/-Cry2-/- mice. ** p< 0.01; ***p< 0.001. 
 
